To evaluate the influence of diabetes on the permeation of dexamethasone acetate(DA) and dexamethansone sodium phosphate(DSP), the two major dexamethansone esters in clinical practice, when applied percutaneously, histochemical staining was used to determine the skin morphology; improved Franz diffusion cells and microdialysis were used to assess the percataneous permeation of DA and DSP in normal and diabetic rats.Histopathological examination showed that the epidermal tissue of diabetic rat was much thinner, the epidermal cell layer was less clear, and the stratified arrangement of epidemic cell had almost disappeared and progressive atrophy were developed on thesubcutaneous fat.In vitro studies showed that the cumulative and the penetrated DSP amount in Group DM were higher.The mean flux value and the mean depositional amount of Group DM were increased significantly compared to those of Group CTL, whereas the amount of DA penetrating was of no difference.Microdialysis indicated that there was no significant difference between Group CTL and Group DM for all the pharmacokinetic parameters of DA.In contrast, the subcutaneous AUCall values and the Cmax of DSP were significantly increased compared to the control.In conclusion, diabetic rat skin significantly increased the percutaneous permeation of DSP but had no effect on that of DA.It suggests that patients with diabetes should consider the dose of administration when using DA, DSP or other glucocorticoids topically, as different liposolubilities may play some role in the permeability of these componnds via diabetic skin.